HeartWare tells cardiac surgeons to inspect a component of its HVAD heart pump that's failed in a small number of patients.

HeartWare International (NSDQ:HTWR) said it's issuing a "field correction" to cardiac surgeons, advising them to check a component of its HVAD implanted heart pump that's been reported to fail in less than 0.004% of some 2,900 implants.
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
The New York Times lists the 10 most expensive hospitals in the United States, based on CMS data